All Stories

  1. VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways

    Article • British Journal of Pharmacology, August 2018, Wiley

    Professor Javier Fernández-Ruiz

  2. The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes

    Article • British Journal of Pharmacology, July 2018, Wiley

    Professor Javier Fernández-Ruiz

  3. Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis

    Article • British Journal of Pharmacology, May 2018, Wiley

    Professor Javier Fernández-Ruiz

  4. Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome

    Article • Pharmacology Research & Perspectives, March 2016, Wiley

    Professor Javier Fernández-Ruiz

  5. Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia

    Article • British Journal of Pharmacology, July 2015, Wiley

    Professor Javier Fernández-Ruiz

  6. A Sativex®-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis

    Article • British Journal of Pharmacology, May 2015, Wiley

    Professor Javier Fernández-Ruiz

  7. The endocannabinoid system is altered in the post‐mortem prefrontal cortex of alcoholic subjects

    Article • Addiction Biology, July 2014, Wiley

    Dr Luis F Callado, Professor Javier Fernández-Ruiz, Stephen Alexander

  8. Changes in Endocannabinoid Receptors and Enzymes in the Spinal Cord of SOD1G93ATransgenic Mice and Evaluation of a Sativex®-like Combination of Phytocannabinoids: Interest for Future Therapies in Amyotrophic Lateral Sclerosis

    Article • CNS Neuroscience & Therapeutics, April 2014, Wiley

    Professor Javier Fernández-Ruiz

  9. Changes in CB1 and CB2 receptors in the post‐mortem cerebellum of humans affected by spinocerebellar ataxias

    Article • British Journal of Pharmacology, March 2014, Wiley

    Professor Javier Fernández-Ruiz